Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**MCM vaccine** is an investigational, preclinical tumor-mRNA cancer vaccine developed at the University of Florida for glioblastoma and glioma. It consists of total tumor-derived mRNA organized in an \"onion-like\" microgel-chemokine-mRNA complex and administered subcutaneously. In a murine intracranial glioma model, the formulation promoted intratumoral immune activation, including dendritic-cell and natural-killer-cell recruitment, T-cell activation and infiltration, and pro-inflammatory M1-like microglial reprogramming. Its antitumor activity was associated with tumor CCL4 upregulation and signaling through the CCL4-CCR5 axis; CCL4 blockade eliminated the observed survival benefit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MCM vaccine.